OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
MWN-AI** Summary
OKYO Pharma Limited, a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced on February 12, 2026, a public offering of ordinary shares priced at $1.85 each. The underwritten offering includes 10,815,000 shares, aiming to raise approximately $20 million in gross proceeds. Additionally, the underwriter has a 30-day option to purchase up to 1,622,250 extra shares, which could bring the total proceeds to about $23 million if fully exercised.
The company plans to use the proceeds primarily for further clinical development of its candidates, alongside general corporate purposes and working capital. Piper Sandler & Co. is the sole manager for this offering, which is projected to close around February 17, 2026, pending customary closing conditions.
OKYO Pharma's shares are traded on the Nasdaq Capital Market, and the offering follows a shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC), declared effective earlier in February. The offering materials, including a preliminary prospectus supplement and a base prospectus, are accessible through the SEC's website and from Piper Sandler.
The company is in a notable phase of development, having successfully completed a Phase 2 trial for its lead drug, urcosimod, and is preparing to initiate a Phase 2b/3 study involving approximately 150 subjects this year. The announcement includes standard forward-looking statements cautioning investors about potential risks and uncertainties affecting actual results.
For investor inquiries, OKYO Pharma's contact information is provided for further assistance.
MWN-AI** Analysis
OKYO Pharma Limited's announcement of a $20 million public offering of ordinary shares at $1.85 per share highlights its ongoing focus on developing therapies for neuropathic corneal pain (NCP) and other inflammatory eye diseases. This capital raise comes at a critical juncture following the company's successful Phase 2 trial of its leading candidate, urcosimod. The proceeds from the offering, intended for clinical development and operational expenses, position OKYO to enhance its research and potentially expedite bringing its products to market.
From a market analysis perspective, the pricing of $1.85 suggests strategic positioning below recent trading levels, aimed at encouraging investor participation while addressing immediate financial needs. Given that OKYO's technology addresses niche yet potentially lucrative therapeutic areas in ophthalmology, the successful completion of this offering may bolster investor confidence.
However, while the immediate infusion of capital is promising, prospective investors should consider the inherent risks associated with clinical-stage biotech firms, including the unpredictability of clinical trial outcomes and regulatory approvals. The broader biotech sector has been volatile, influenced by market conditions and investor sentiment towards riskier assets.
In addition, the option for underwriters to purchase additional shares if demand is strong signals robust interest, which could provide downward pressure on the share price post-offering as shares enter the market.
Investors looking to enter or expand their positions in OKYO should monitor the company’s upcoming Phase 2b/3 trial results, as these data points will be crucial for evaluating the potential upside and market valuation. Long-term investment perspectives should weigh the company's pipeline and therapeutic potentials against the risks associated with its clinical development phases. A wait-and-see approach, combined with an assessment of trial outcomes, may be prudent for new investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an underwritten public offering (the “Offering”) of 10,815,000 ordinary shares at an offering price of $1.85 per ordinary share. The Company has granted the underwriter a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the public offering price, less underwriting discounts and commissions.
The gross proceeds to the Company from the Offering, before deducting offering expenses payable by the Company and discounts, will be approximately $20 million. Assuming full exercise by the underwriter of its option to purchase additional ordinary shares, the gross proceeds to the Company from the Offering would be approximately $23 million, before deducting offering expenses payable by the Company and discounts. The Company intends to use the net proceeds from the Offering primarily for clinical development of its product candidates, general corporate purposes and working capital.
Piper Sandler & Co. is serving as the sole manager for the Offering. The Offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.
The securities are being offered and sold pursuant to a shelf registration statement on Form F-3 (File No. 333-293145), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2026, and declared effective on February 10, 2026. The Offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus, as may be further supplemented by any free writing prospectus that the Company may file with the SEC. The final prospectus supplement relating to the Offering will be filed with the SEC and will also be available on the SEC’s website. Copies of the preliminary prospectus supplement, the final prospectus supplement (when available) and the accompanying base prospectus relating to the Offering can also be obtained from Piper Sandler & Co. at 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attn: Prospectus Department, or via email at prospectus@psc.com or telephone at (800) 747-3924.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.
Forward-Looking Statements
Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the closing of the Offering and the expected use of proceeds from the Offering. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the Offering, risks disclosed in the section titled “Risk Factors” included in the preliminary prospectus supplement filed with the SEC on February 12, 2026, and risks disclosed in other documents the Company files from time to time with the SEC. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
OKYO Pharma Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com
FAQ**
How does the pricing of the public offering by OKYO Pharma Limited OKYO at $1.85 per share compare to the historical stock performance in London and New York?
What implications does the $million gross proceeds from OKYO Pharma Limited OKYO's public offering have for its future clinical development efforts in both London and New York markets?
How might the engagement of Piper Sandler & Co. as the sole manager for the OKYO Pharma Limited OKYO offering influence investor sentiment in major financial hubs like London and New York?
What are the anticipated impacts of OKYO Pharma Limited OKYO’s upcoming Phase 2b/3 multiple-dose study on its market valuation in both London and New York?
**MWN-AI FAQ is based on asking OpenAI questions about OKYO Pharma Limited (NASDAQ: OKYO).
NASDAQ: OKYO
OKYO Trading
-4.41% G/L:
$1.625 Last:
29,968 Volume:
$1.67 Open:
